Literature DB >> 11346422

Analysis of the performance characteristics of the University of Washington Quality of Life instrument and its modification (UW-QOL-R).

E A Weymuller1, R Alsarraf, B Yueh, F W Deleyiannis, M D Coltrera.   

Abstract

BACKGROUND: During a 5-year period, we analyzed 3 patient subsets from the University of Washington Quality of Life (UW-QOL) Registry and published the results. In each instance, editorial review has raised legitimate concerns regarding the UW-QOL instrument that deserve public comment. We present our response to these criticisms. Since our original publication (1993), we have added domains to the original UW-QOL instrument. These additions reflected our concern that we might be missing important elements in the spectrum of disease-specific response to treatment. Using the data we have accumulated in the last 5 years, we present an analysis of the internal consistency of the UW-QOL. We have identified those domains that are responsive (or not responsive) to treatment effect and have revised the UW-QOL accordingly to create the UW-QOL-R, which is recommended for future use.
DESIGN: The project began January 1, 1993, after approval by the UW Human Subjects Committee. Critical comments offered by external review were collated and responded to. Internal consistency was evaluated by interitem correlation matrix (Cronbach alpha) testing.
SUBJECTS: All new patients presenting to the UW Medical Center (Seattle) with a diagnosis of head and neck cancer were asked to participate in a prospective analysis of QOL changes during and after treatment. INTERVENTION: Patients completed the pretreatment QOL questionnaire on the day of their initial workup. The format for the pretreatment test was an interviewer-supervised self-administered test; the subsequent tests were self-administered and were completed at 3, 6, 12, 24, and 36 months. Other data entered for each patient included site, stage, treatment, histologic classification, reconstruction, and current status. A QOL registrar was responsible for patient follow-up, data collection, and collation. All data were entered into the departmental relational database.
RESULTS: Criticisms by external review included the following: "it is improper to call it [UW-QOL] a measure of quality of life"; "the summary scale is problematic because it implies that each of the subscales are weighted or 'valued' equally"; "some domain questions relate to surgery specific issues. while others are specific to radiation"; "we were confused by the scoring"; and "the UW-QOL index does not specifically address the psychological impact of the disease and its treatment." After evaluation of internal consistency, the UW-QOL was modified by removing 2 domains that correlated poorly with the others. This resulted in a 10-item instrument (UW-QOL-R) with an overall internal consistency score of 0.85.
CONCLUSIONS: The UW-QOL can be effectively and accurately used to compare treatment effects in the management of head and neck cancer. With this revised instrument, the 10 items appear to measure the domains of overall QOL in a highly consistent and reliable fashion over time.

Entities:  

Mesh:

Year:  2001        PMID: 11346422     DOI: 10.1001/archotol.127.5.489

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  35 in total

Review 1.  Global registries for measuring pharmacoeconomic and quality-of-life outcomes: focus on design and data collection, analysis and interpretation.

Authors:  Lisa Kennedy; Ann-Marie Craig
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  Xerostomia health-related quality of life: NRG oncology RTOG 0537.

Authors:  Gwen Wyatt; Stephanie L Pugh; Raimond K W Wong; Stephen Sagar; Anurag K Singh; Shlomo A Koyfman; Phuc F Nguyen-Tân; Sue S Yom; Francis S Cardinale; Khalil Sultanem; Ian Hodson; Greg A Krempl; Barbara Lukaszczyk; Alexander M Yeh; Lawrence Berk
Journal:  Qual Life Res       Date:  2016-02-25       Impact factor: 4.147

3.  Long-term functional outcomes and patient perspective following altered fractionation radiotherapy with concomitant boost for oropharyngeal cancer.

Authors:  Bena Cartmill; Petrea Cornwell; Elizabeth Ward; Wendy Davidson; Sandro Porceddu
Journal:  Dysphagia       Date:  2012-02-24       Impact factor: 3.438

4.  Observations of benefit finding in head and neck cancer patients.

Authors:  Sandra Cavell; Elizabeth Broadbent; Liesje Donkin; Kim Gear; Randall P Morton
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-01-30       Impact factor: 2.503

5.  Development and validation of the nasopharyngeal cancer scale among the system of quality of life instruments for cancer patients (QLICP-NA V2.0): combined classical test theory and generalizability theory.

Authors:  Jiayuan Wu; Liren Hu; Gaohua Zhang; Qilian Liang; Qiong Meng; Chonghua Wan
Journal:  Qual Life Res       Date:  2016-02-29       Impact factor: 4.147

6.  Variables Associated With Communicative Participation After Head and Neck Cancer.

Authors:  Susan Bolt; Tanya Eadie; Kathryn Yorkston; Carolyn Baylor; Dagmar Amtmann
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-12-01       Impact factor: 6.223

7.  Exploratory Factor Analysis of NRG Oncology's University of Washington Quality of Life Questionnaire-RTOG Modification.

Authors:  Stephanie L Pugh; Gwen Wyatt; Raimond K W Wong; Stephen M Sagar; Bevan Yueh; Anurag K Singh; Min Yao; Phuc Felix Nguyen-Tan; Sue S Yom; Francis S Cardinale; Khalil Sultanem; D Ian Hodson; Greg A Krempl; Ariel Chavez; Alexander M Yeh; Deborah W Bruner
Journal:  J Pain Symptom Manage       Date:  2016-11-27       Impact factor: 3.612

8.  A prospective investigation of swallowing, nutrition, and patient-rated functional impact following altered fractionation radiotherapy with concomitant boost for oropharyngeal cancer.

Authors:  Bena Cartmill; Petrea Cornwell; Elizabeth Ward; Wendy Davidson; Sandro Porceddu
Journal:  Dysphagia       Date:  2011-02-23       Impact factor: 3.438

9.  Quality of life after treatment of laryngeal carcinoma: a single centre cross-sectional study.

Authors:  J S Williamson; D Ingrams; H Jones
Journal:  Ann R Coll Surg Engl       Date:  2011-11       Impact factor: 1.891

10.  Photodynamic therapy with meta-tetrahydroxyphenylchlorin (Foscan) in the management of squamous cell carcinoma of the head and neck: experience with 35 patients.

Authors:  Kai Johannes Lorenz; Heinz Maier
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-03-17       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.